Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...
Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...
American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will feature nearly 300 educational sessions with more than 1,700 speakers discussing the latest ...
Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback